Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

On August 1, 2022 Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time (Press release, Chemomab, AUG 1, 2022, View Source [SID1234617200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the event, Chemomab’s management team will review second quarter 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.

A replay of the call will be available on Chemomab’s website for 90 days at www.chemomab.com.

Live Webcast and Conference Call at 8:00 am Eastern Time, Friday, August 12, 2022

Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.

Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.